Tag:
AcelRx
Latest Headlines
Latest Headlines
Venture firm preps $100M fund for late-stage life sciences investments
Following a well-defined trail of venture groups into late-stage investing, San Francisco-based Foresite Capital Management says it has wrapped a $100 million fund that will be heavily focused on the most disruptive and most promising late-stage technology it can find in biotech, genomics and diagnostics, among other healthcare fields.
AcelRx shares soar on positive, head-to-head pain drug study
AcelRx Pharmaceuticals shares got a big boost this morning after the biotech announced that its post-operative pain therapy--the Sufentanil NanoTab PCA (patient-controlled analgesia) System--was not only not inferior to the standard IV morphine but also beat it on a key measurement score while gaining kudos from nurses and patients.
AcelRx gets $20M loan for Phase III work
AcelRx Pharmaceuticals has secured a $20 million loan from Hercules Technology Growth Capital. Earlier this year, the developer attempted to raise $86 million in its IPO, but, like many biotech
WSJ analysis offers a bleak outlook for new biotech IPOs
The Wall Street Journal offers its own bleak assessment of the biotech IPO market this morning, reviewing a string of disappointing offerings capped by Tranzyme's decision to cut its price from the
AcelRx falls short in $40M IPO
AcelRx Pharmaceuticals aimed high but fell short. The Redwood City, CA-based devloper had hoped to raise $86 million in an initial offering of 8 million shares at $12 to $14 per share. But the
Biotechs braving stormy IPO waters to raise cash
A pair of life sciences companies which went public on Friday morning saw their shares surge upward in the afternoon. But the gains came only after each had chopped a huge chunk off their projected
AcelRx will try to sell investors on an $86M IPO
Despite plenty of recent evidence of investors' lukewarm appetite for biotech IPOs, AcelRx Pharmaceuticals has announced plans to try and raise $86 million in an initial offering. There's no word yet
